Bioorganic & Medicinal Chemistry Letters 28 (2018) 562–565

Contents lists available at ScienceDirect

Bioorganic & Medicinal Chemistry Letters

journal homepage: www.elsevier.com/locate/bmcl

Multiple-step, one-pot synthesis of 2-substituted-3-phosphono-1-thia-4-aza-2-cyclohexene-5-carboxylates and their corresponding ethyl esters

Dunxin Shen [a], Kenneth Hensley [b], Travis T. Denton [a,*]

[a] Department of Pharmaceutical Sciences, College of Pharmacy, Washington State University, Spokane, WA 99201, United States
[b] Arkansas College of Osteopathic Medicine, Fort Smith, AR 72916, United States

ARTICLE INFO

Article history:
Received 10 October 2017
Revised 22 January 2018
Accepted 25 January 2018
Available online 1 February 2018

Keywords:
Autophagy
Lanthionine ketimine
Neurodegenerative diseases
ALS
Alzheimer's
Cysteine
Phosphonate
Arbuzov

ABSTRACT

The multiple-step, one-pot procedure for a series of 2-substituted-3-phosphono-1-thia-4-aza-2-cyclohexene-5-carboxylates, analogues of the natural, sulfur amino acid metabolite lanthionine ketimine (LK), its 5-ethyl ester (LKE) and 2-substituted LKEs is described. Initiating the synthesis with the Michaelis-Arbuzov preparation of α-ketophosphonates allows for a wide range of functional variation at the 2-position of the products. Nine new compounds were synthesized with overall yields range from 40 to 62%. In addition, the newly prepared 2-isopropyl-LK-P, 2-*n*-hexyl-LKE-P and 2-ethyl-LKE were shown to stimulate autophagy in cultured cells better than that of the parent compound, LKE.

Lanthionine ketimine (LK, (5*R*)-3, 5-dicarboxy-1-thia-4-aza-2-cyclohexene) is a natural compound first described as an alternative product of the mammalian transsulfuration pathway arising from the metabolism of homocysteine, in which cystathionine beta synthase (CβS) and glutamine transaminase K (GTK) are integral components.[1,2] Although the specific target of LK remains elusive, LK, and its more cell membrane permeable analogue, lanthionine ketimine ethyl ester (LKE), have been shown to possess multiple neuroprotective, anti-neuroinflammatory and neurotrophic activities.[2–11] Chief amongst the biological actions of LKE is its ability to promote autophagy in cells and *in vivo*.[12,13] LKE penetrates the blood-brain barrier and is more potent than LK in cell culture assays, possibly due to increased lipophilicity, inherent to the esterified 5-carboxylate group.[7,12,13] LKE increases lifespan and slows decline of motor function in the $SOD1^{G93A}$ mouse model of amyotrophic lateral sclerosis (ALS),[14] decreases production of native Aβ(1-40) in SH-SY5Y cells,[5] decreases amyloid burden inside neurons and in plaques,[5] decreases protein phosphorylated-tau accumulation,[5] decreases microglial activation[9] and slows cognitive decline in the 3×Tg-AD mouse model of Alzheimer's disease (AD).[5,7] Besides neurodegenerative diseases, preclinical rodent studies indicate stroke and glioma as additional disease targets of LKE and its analogues.[6,15] Although the exact molecular target of LK(E) has not yet been identified, past studies have identified collapsin response mediator protein-2 (CRMP2), an adaptor protein involved in neurite outgrowth via interaction with tubulin dimers, cyclin-dependent kinase 5 (CDK5) and glycogen synthase kinase 3β (GSK-3β), synaptic plasticity, vesicular trafficking and autophagy regulation.[16,17] The effects of lanthionine ketimine may result from the compound's ability to engage CRMP2 pathways to alter localization of the protein mTOR (mammalian target of rapamycin) and, thus, promote beneficial autophagy.[2,12]

Due to the necessity for new compounds in the fight against neurological disorders such as ALS, AD and Parkinson's disease, we set out to prepare new analogues of LK and LKE. To do so, modifications were made to the preexisting synthetic strategy to incorporate substituents on the 2-position of LK(E)s (Scheme 1). The synthesis of 2-substituted-LKEs begins by the bromination of α-ketocarboxylic acids, **1**, by treatment with bromine for one hour in refluxing dichloromethane. After removal of the solvent and excess bromine, the brominated acid is reacted with an aqueous solution of cysteine ethyl ester hydrochloride (**3**) to afford the 2-substituted LKEs (**4**). An important feature of LKE as a drug

* Corresponding author.
E-mail address: travis.denton@wsu.edu (T.T. Denton).

https://doi.org/10.1016/j.bmcl.2018.01.052
0960-894X/



Scheme 1. Synthetic sequence for the preparation of 2-substituted-LKEs.

candidate is its relatively small size and possession of functional groups that can be further modified, while remaining within the accepted parameters of the rule of five for druglikeness.[18] We reasoned that amongst the potential modes of target engagement, electrostatic interaction of the 3-carboxylate group has a high probability of importance, which could possibly be further enhanced by increasing the charge density or the hydrogen bonding opportunities near this corner of the molecule. Thus, we designed a synthetic sequence to prepare 3-phosphonate analogues of LK(E), namely lanthionine ketimine (ester) phosphonates (LK(E)-Ps, Scheme 2). The synthesis of 2-substituted-LK(E)-Ps begins with the preparation of dimethyl α-ketophosphonates (DMAKPs, **6**), utilizing standard Michaelis-Arbuzov (MA) reaction conditions. α-Ketophosphonate diesters are extremely reactive towards nucleophiles, therefore, to avoid any unnecessary side reactions, the remaining transformations were all performed in the same pot. Accordingly, following the MA reaction, the methyl chloride by-product and excess trimethyl phosphite were removed by simple rotary evaporation. The crude dimethyl α-ketophosphonates (**6**) were dissolved in excess trimethylsilyl bromide (TMS-Br) and heated to 100 °C, using microwave irradiation, for ten minutes to afford the intermediate bis-TMS esters (**7**). After removal of the excess TMS-Br and methyl bromide, intermediates **7** were brominated by treatment of the crude reaction mixture with bromine in refluxing dichloromethane for one hour. After removal of the solvent and excess bromine, the crude intermediates were treated with water for three minutes to hydrolyze the bis-TMS esters to the diacid form before reacting with cysteine ethyl ester hydrochloride (**3**) or cysteine hydrochloride (**9**) to afford the LKE-Ps or LK-Ps, respectively. Most products precipitated from the final, aqueous reaction system as white to off-white solids.

During conditions screening, the reaction mixtures would often turn very dark after the bromination step of the sequence. It was suspected that the sulfur containing intermediates were being oxidized, and ultimately polymerized, by the bromine that was not completely removed from the previous reaction. In an effort to eliminate this problem, in the final step, where the brominated intermediate is reacted with the amino acid, a 5% aqueous sodium bisulfite solution was used as the reaction solvent in place of pure water to serve as a reductant to neutralize any remaining bromine from the previous reaction. The addition of the reducing agent both protected the reaction from becoming dark in color and ultimately increased the overall yield of the precipitated products. The final, solid materials were collected by centrifugation, triturated with ethyl ether and isolated by vacuum filtration.

Using these procedures, two 2-substituted LKEs and seven 2-substututed LK(E)-Ps were prepared (Table 1) and their structures were confirmed by ^{1}H, ^{13}C and ^{31}P NMR and liquid chromatography tandem UV spectrophotometry high-resolution mass spectrometry (LC/UV/HRMS).

Considering the existence of imine-enamine tautomerism, the final product could be in either imine or enamine form. The enamine form was confirmed by one- and two-dimensional NMR analysis. The ^{1}H and ^{13}C NMR spectra for 2-*n*-hexyl-LKE-P are shown in Fig. 1.

Proton assignments were confirmed by the COSY cross peaks between methine proton 1 and the diastereotopic methylene protons 3 and 4 (Supplementary Fig. 1). The smaller, vicinal coupling constant for peak 3 (3.3 Hz) indicates the cis (staggered) orientation of protons 1 and 3 whereas the larger, vicinal coupling constant (6.3 Hz) indicates the trans (antiperiplanar) orientation of protons 1 and 4. The ^{13}C NMR peak assignments for 2-*n*-hexyl-LKE-P are shown in Fig. 1, B. Carbons 1, 2 and 3 were confirmed to be proton-free by DEPT analysis (Supplementary Fig. 2. The chemical shift of carbon 1 is 170.5 ppm, indicative of a carbonyl carbon. The remaining two, proton-free, alkene (enamine) carbons give rise to the doublet at 127.0 ppm with a coupling constant (J = 192.5 Hz) significantly larger than the doublet at 110.3 ppm (J = 17.5 Hz) resulting in the assignments made. Carbons 4–11 were also confirmed by DEPT and HSQC analysis (Supplementary information). According to the peak assignment of 2-*n*-hexyl-LKE-P, all other synthesized LK(E)-Ps were characterized accordingly.

Upon analysis of 2-benzyl-LK-P and 2-ethyl-LKE, some intriguing features were revealed in the ^{1}H NMR spectra. The two methylene (benzyl) protons in 2-benzyl-LK-P are split into a quartet. This peak should be, theoretically, a simple singlet integrating to two protons. This quartet was confirmed to represent the benzyl protons by HSQC analysis (Supplementary Fig. 4). Correspondingly, the methylene protons in 2-ethyl-LKE, which should be split into a quartet, are split into two multiplets, each integrating to a single proton. The two multiplets were confirmed to be the methylene protons of the 2-ethyl group by HSQC analysis (Supplementary Fig. 5). We hypothesize that the benzyl and ethyl groups have restricted rotation about the CH_2-alkene (enamine) bond, thus generating two distinguishable rotamers at room temperature, although this does not explain the multiplicity of the benzyl pro-



Scheme 2. Synthetic sequence for the preparation of 2-substituted-LK(E)-Ps.